Long-acting depot formulations of naltrexone for heroin dependence: a review
- PMID: 20224403
- DOI: 10.1097/YCO.0b013e3283386578
Long-acting depot formulations of naltrexone for heroin dependence: a review
Abstract
Purpose of review: The major problem with the oral formulation of naltrexone for heroin dependence is poor compliance (adherence). Long-acting sustained release formulations of naltrexone (implantable and injectable) might help to improve compliance and, thus, increase the efficacy of abstinence-oriented treatment of heroin dependence with naltrexone.
Recent findings: There have been several implantable and injectable formulations of naltrexone developed within the last decade. It was demonstrated that some of them are effective and relatively well tolerated medications for relapse prevention in heroin addicts. However, advantages and disadvantages of these new medications have never been systematically analyzed.
Summary: Long-acting sustained release formulations of naltrexone are well tolerated and more effective for relapse prevention in heroin addicts than the oral ones.
Similar articles
-
Long-acting injectable naltrexone for the treatment of alcohol dependence.Expert Rev Neurother. 2007 Oct;7(10):1265-77. doi: 10.1586/14737175.7.10.1265. Expert Rev Neurother. 2007. PMID: 17939765 Review.
-
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.Addiction. 2013 Sep;108(9):1628-37. doi: 10.1111/add.12208. Epub 2013 May 24. Addiction. 2013. PMID: 23701526 Clinical Trial.
-
Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.Eur Addict Res. 2007;13(4):201-6. doi: 10.1159/000104882. Eur Addict Res. 2007. PMID: 17851241
-
Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26. Biol Psychiatry. 2010. PMID: 20537615 Clinical Trial.
-
[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].Internist (Berl). 1996 Oct;37(10):1061-7; discussion 1067. Internist (Berl). 1996. PMID: 9019453 Review. German. No abstract available.
Cited by
-
Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.Subst Abuse. 2012;6:115-33. doi: 10.4137/SART.S9031. Epub 2012 Sep 27. Subst Abuse. 2012. PMID: 23055738 Free PMC article.
-
Medication-Assisted Treatment and Violent Outcomes in Community-Based Offenders with Alcohol and Drug Use Problems.Psychol Violence. 2016 Jul;6(3):378-389. doi: 10.1037/vio0000047. Epub 2016 Mar 24. Psychol Violence. 2016. PMID: 27525168 Free PMC article.
-
Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology. 2022 Jul;47(8):1431-1439. doi: 10.1038/s41386-022-01311-7. Epub 2022 Mar 28. Neuropsychopharmacology. 2022. PMID: 35351961 Free PMC article. Review.
-
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Drug Alcohol Depend. 2015 Dec 1;157:158-65. doi: 10.1016/j.drugalcdep.2015.10.023. Epub 2015 Oct 28. Drug Alcohol Depend. 2015. PMID: 26560326 Free PMC article. Clinical Trial.
-
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. doi: 10.3109/00952990.2011.653426. Epub 2012 Mar 12. Am J Drug Alcohol Abuse. 2012. PMID: 22404717 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials